Bupropion in pregnancy and the prevalence of congenital malformations

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 5, 2007, Pages 474-484

  Cole, J Alexander ^a   Modell, Jack G ^b   Haight, Barbara R ^b   Cosmatos, Irene S ^b   Stoler, Joan M ^c   Walker, Alexander M ^a  

^a Department of Epidemiology ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressants; Bupropion; Cardiovascular malformations; Congenital malformations; First trimester; Insurance claims; Odds ratio; Pregnancy; Prevalence; Taratogen

Indexed keywords

AMFEBUTAMONE; AMINOGLYCOSIDE; ANDROGEN; ANTIDEPRESSANT AGENT; BUSULFAN; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETRETINATE; FLUCONAZOLE; INDOMETACIN; ISOTRETINOIN; LITHIUM; METHOTREXATE; MISOPROSTOL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PARAMETHADIONE; PENICILLAMINE; PHENYTOIN; PROPYLTHIOURACIL; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; THIAMAZOLE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HEALTH CARE COST; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TERATOGENICITY;

ABNORMALITIES; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DATABASES, FACTUAL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; MALE; MATERNAL AGE; MIDDLE AGED; ODDS RATIO; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 34249747833     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1296     Document Type: Article

References (29)

1. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-1834.
2. GlaxoSmithKline. Wellbutrin [package insert]. Research Triangle Park, NC, 2006.
3. GlaxoSmithKline. Zyban [package insert]. Research Triangle Park, NC, 2006.
4. Tucker WE, Jr. Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 1983; 44: 60-62.
5. White AD, Andrews EB. The Pregnancy Registry Program at Glaxo Wellcome Company. J Allergy Clin Immunol 1999; 103: S362-S363.
6. Eldridge RR, Ephross SA, Heffner CR, Tennis PS, Stender DM, White AD. Monitoring pregnancy outcomes following prenatal drug exposure through prospective pregnancy registries and passive surveillance: a pharmaceutical company commitment. Prim Care Update Ob Gyns 1998; 5: 190-191.
7. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after pre-natal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159-163.
8. Bupropion (amfebutamone): caution during pregnancy. Pre-scrire Int 2005; 14: 225.
9. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192: 932-936.
10. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767-773.
11. Schiveley AL, Ashley MT, Gregory DF. Bupropion exposure during pregnancy: a case report. J Pediat Pharm Practice 2000; 5: 247-249.
12. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. CMAJ 2005; 173: 1320-1321.
13. Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000; 9: 549-556.
14. Briggs GG. Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 2002; 45: 6-21.
15. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338: 1128-1137.
16. Cunningham FG, Williams JW. Williams obstetrics. McGraw-Hill: New York, 2001; x, 1668.
17. Appendix A. Teratology 2000; 61: 159-160.
18. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999; 59: 1-2.
19. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001; 107: E32.
20. Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60: 356-364.
21. Pradat P, Francannet C, Harris JA, Robert E. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol 2003; 24: 195-221.
22. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264-1269.
23. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-610.
24. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713-718.
25. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89-94.
26. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
27. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-2248.
28. McElhatton PR, Garbis HM, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285-294.
29. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-508.